|Dr. Matthew C. Coffey Ph.D., M.B.A.||Chief Exec. Officer, Pres and Director||568.07k||N/A||N/A|
|Mr. Kirk J. Look CA||Chief Financial Officer||459.96k||N/A||N/A|
|Dr. Andres A. Gutierrez M.D., Ph.D.||Chief Medical Officer||75.04k||N/A||56|
|Mr. Andrew R. de Guttadauro||Pres of Oncolytics Biotech (U.S.) Inc||N/A||N/A||50|
|Dr. Daniel Douglas Von Hoff M.D., F.A.C.P.||Consultant||N/A||N/A||69|
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancers. The company is developing REOLYSIN, a systemically administered immune-oncology viral agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.
Oncolytics Biotech Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.